In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|August 29, 2018
New Mass Spec Software Simplifies Data Analysis
Author(s)BioPharm International Editors
Shimadzu’s Imagereveal MS mass spectrometry imaging data analysis software can analyze large sets of data or simultaneously analyze multiple sets of data.
Advertisement
The Imagereveal MS mass spectrometry imaging data analysis software from Shimadzu simplifies the data analysis process by enabling data to be analyzed from a variety of perspectives without requiring extra time or effort. The software is suited to analyze large sets of data or simultaneously analyze multiple sets of data.
Mass spectrometry imaging is used to analyze two-dimensional images that show the distribution of substances measured with a mass spectrometer. The company reports that in recent years, technical advancements in spatial resolution and mass accuracy have generated excessively large amounts of data that inhibit data analysis.
The software resolves these issues by offering functionalities that search massive amounts of mass spectrometry imaging data for the information required, which can dramatically improve research efficiency, as stated by the company. The software includes six types of functionality for data analysis with different availabilities of that functionality depending on the license selected by the user. A data converter can also be used to analyze data measured by a mass spectrometer not manufactured by the company.
Shimadzu will exhibit the software at the Japan Analytical Instruments Manufacturers (JASIS) convention, from Sept. 5–7, 2018 at the Makuhari Messe International Exhibition Hall in Chiba, Japan.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5